Immunology Clinical Trials Update: Week 18, 2026

Published May 1, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Years of Age (COMFORT Toddlers)

This Phase 3 study is testing a peanut allergy patch for very young children aged 1 to 3 years. The patch delivers small doses of peanut protein through the skin to help manage peanut allergies in a safer and easier way than traditional methods. The trial is recruiting in several countries and will monitor the patch’s safety over six months, which could lead to a new option for families managing peanut allergies in toddlers.

In-depth Immunological Investigation of COVID-19

This study is exploring how the immune system responds to COVID-19 by closely examining samples from patients. Understanding these immune responses better could guide the development of improved treatments and ways to protect those affected by the virus. The trial is currently recruiting 100 participants in Belgium and aims to provide important insights into COVID-19 immunity.

The Bloom Infant Probiotic (BIP) Study

This Phase 2 trial looks at whether giving a probiotic to infants who received antibiotics early in life can boost their immune response to vaccines. Antibiotics can disrupt the gut microbiome, which plays a role in immunity, so this study could help improve vaccine protection in these infants. It plans to enroll 360 infants in Australia and involves collecting blood and stool samples alongside routine vaccinations.

Multi OIT to Test Immune Markers After Minimum Maintenance Dose

This Phase 2 study tested a combined treatment using Omalizumab and oral immunotherapy for people with multiple food allergies. The goal was to make treatment safer and allow lower doses of allergens, which is especially helpful for younger patients. The study, completed in the United States with 60 participants, has reported results that may influence future allergy treatments.

Building Cognitive Resilience to Vaccine Misinformation Using AI in Europe

This study is testing an AI chatbot designed to help parents resist misinformation about vaccines and improve their attitudes toward childhood vaccination. If successful, it could offer a widely accessible tool to support informed vaccine decisions and enhance public health across Europe. The trial plans to enroll 5,000 participants but has not yet started recruiting.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.